[Screening for transitional cell carcinoma of the bladder with trophoblastic differentiation in Upper Galilee].

Urinary bladder carcinoma with trophoblastic differentiation (TD) is a variant of urothelial (transitional cell) carcinoma (TCC) which secretes placental proteins, predominantly beta-human chorionic gonadotropin (HCG). An aggressive clinical course and a poor prognosis are characteristic of this tumor. We evaluated the frequency and clinical and pathological appearance of TCC-TD in the Upper Galilee and Golan Heights between 1988 and 1995 inclusive.

An approach for high sensitivity detection of prostate cancer by analysis of changes in structuredness of the cytoplasmic matrix of lymphocytes specifically induced by PSA-ACT.

Purpose: An alternative procedure for detection of prostate cancer was examined based on the observation that cells reexposed in vitro to antigenic or mitogenic stimulation will change their intracellular structuredness as measured by polarization of fluorescent light emitted by labeled cells (SCM test).

Materials And Methods: Lymphocytes derived from patients bearing a nonmalignant prostate tumor and healthy individuals were exposed to PSA-ACT, PHA, and MUC-1.

Results: Of sixty-five patients with prostate carcinoma (CaP), sixty-two were correctly diagnosed by the test.

[Urinary bladder transitional cell carcinoma with trophoblastic differentiation].

Transitional cell carcinoma (TCC) with trophoblastic differentiation (TD) is a newly recognized variant of urothelial cancer which produces placental proteins, predominantly beta-human chorionic gonadotropin (HCG). It has a poor prognosis. About 210 cases were described, mostly from North America, Europe and Japan.

Radionuclide assessment of bladder-emptying function in normal male population and in patients before and after prostatectomy.

Radionuclide assessment of the bladder-emptying function was evaluated in 82 normal individuals and in 16 patients before and after prostatectomy. The parameters evaluated were: average flow rate (AFR), peak flow rate (PFR), corrected peak flow rate (CPFR = PFR/[bladder volume] 0.5), ejection fraction (EF) of the bladder, and post-voiding residual urine (RU) volume.